BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33116240)

  • 1. Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.
    Monti P; Lionetti M; De Luca G; Menichini P; Recchia AG; Matis S; Colombo M; Fabris S; Speciale A; Barbieri M; Gentile M; Zupo S; Dono M; Ibatici A; Neri A; Ferrarini M; Fais F; Fronza G; Cutrona G; Morabito F
    Sci Rep; 2020 Oct; 10(1):18427. PubMed ID: 33116240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.
    Hu B; Patel KP; Chen HC; Wang X; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating M; Wierda WG
    Br J Haematol; 2019 Nov; 187(3):307-318. PubMed ID: 31243771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.
    Yu L; Kim HT; Kasar S; Benien P; Du W; Hoang K; Aw A; Tesar B; Improgo R; Fernandes S; Radhakrishnan S; Klitgaard J; Lee C; Getz G; Setlur SR; Brown JR
    Clin Cancer Res; 2017 Feb; 23(3):735-745. PubMed ID: 27503198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
    Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep targeted sequencing of
    Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
    Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.
    Hoechstetter MA; Busch R; Eichhorst B; Bühler A; Winkler D; Bahlo J; Robrecht S; Eckart MJ; Vehling-Kaiser U; Jacobs G; Jäger U; Hurtz HJ; Hopfinger G; Hartmann F; Fuss H; Abenhardt W; Blau I; Freier W; Müller L; Goebeler M; Wendtner C; Fischer K; Herling CD; Starck M; Bentz M; Emmerich B; Döhner H; Stilgenbauer S; Hallek M
    Leukemia; 2020 Apr; 34(4):1038-1051. PubMed ID: 32042081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
    Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
    Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
    Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
    Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.
    Roos-Weil D; Nguyen-Khac F; Chevret S; Touzeau C; Roux C; Lejeune J; Cosson A; Mathis S; Feugier P; Leprêtre S; Béné MC; Baron M; Raynaud S; Struski S; Eclache V; Sutton L; Lesty C; Merle-Béral H; Cymbalista F; Ysebaert L; Davi F; Leblond V;
    Genes Chromosomes Cancer; 2018 Nov; 57(11):533-540. PubMed ID: 30203893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
    Griffin R; Wiedmeier-Nutor JE; Parikh SA; McCabe CE; O'Brien DR; Boddicker NJ; Kleinstern G; Rabe KG; Bruins L; Brown S; Bonolo de Campos C; Ding W; Leis JF; Hampel PJ; Call TG; Van Dyke DL; Kay NE; Cerhan JR; Yan H; Slager SL; Braggio E
    Blood Adv; 2023 Jul; 7(13):3169-3179. PubMed ID: 36877634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
    Zenz T; Kröber A; Scherer K; Häbe S; Bühler A; Benner A; Denzel T; Winkler D; Edelmann J; Schwänen C; Döhner H; Stilgenbauer S
    Blood; 2008 Oct; 112(8):3322-9. PubMed ID: 18689542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.
    Fontecha MB; Anadón MDR; Mercado Guzmán V; Stanganelli C; Galvano C; Tosin F; Bordone J; Bezares R; Rodríguez C; Heller V; Slavutsky I; Fundia AF
    Ann Hematol; 2024 May; ():. PubMed ID: 38743086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
    Molica S; Shanafelt TD; Giannarelli D; Gentile M; Mirabelli R; Cutrona G; Levato L; Di Renzo N; Di Raimondo F; Musolino C; Angrilli F; Famà A; Recchia AG; Chaffee KG; Neri A; Kay NE; Ferrarini M; Morabito F
    Am J Hematol; 2016 Nov; 91(11):1090-1095. PubMed ID: 27465919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
    Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
    Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
    Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
    Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
    Shindiapina P; Brown JR; Danilov AV
    Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
    Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A
    Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.